Published Date: 01 Mar 2023
After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.
Read Full NewsMistletoe therapy may improve the QOL of patients with cancer; however, evidence does not support a survival benefit, limiting its role in routine oncology care.
A phase 2 study suggests that immunotherapy plus radiation could spare some patients with advanced endometrial cancer from chemotherapy.
1.
Advancing Health in Africa
2.
Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma
3.
Cardiomyocytes are shielded from chemotherapy damage by mitochondrial proteins.
4.
Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.
5.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
1.
Understanding Fibrosarcoma: What You Need to Know
2.
The Power of White Blood Cells: How They Help Keep Us Healthy
3.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
4.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
5.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
3.
Navigating the Complexities of Ph Negative ALL - Part VI
4.
Navigating the Complexities of Ph Negative ALL - Part XIV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation